BRISBANE, Australia, May 16 /PRNewswire-FirstCall/ -- Progen Industries (NASDAQ:PGLAF)(ASX:PGL) today announced it has received notification from the US Food and Drug Administration (FDA...
BRISBANE, Australia, Aug. 9 /PRNewswire-FirstCall/ -- Australian cancer drug development company Progen Industries Limited (ASX:PGLASX:Nasdaq:ASX:PGLAF) announced today the expansion of the...
Progen Engages Burrill to Advance PI-88 Partnering Discussions BRISBANE, Australia, June 28 /PRNewswire-FirstCall/ -- Progen Industries Limited (ASX:PGLASX:Nasdaq:ASX:PGLAF) announced today that...
Results of PI-88 Phase II Clinical Trial in Melanoma Presented at ASCO BRISBANE, Australia, May 16 /PRNewswire-FirstCall/ -- Progen Industries Limited (NASDAQ:PGLAF)(ASX:PGL) today announced...
Progen Reports Solid Financial Performance BRISBANE, Australia, Aug. 26 /PRNewswire-FirstCall/ -- Progen Industries Limited (NASDAQ:PGLAFNASDAQ:ASX:NASDAQ:PGL), a progressive Australian...
PI-88 Phase II Clinical Trial Targeting Liver Cancer Launched BRISBANE, Australia, July 13 /PRNewswire-FirstCall/ -- Progen Industries Limited (NASDAQ:PGLAF)(ASX:PGL), an oncology-focused drug...
U.S. FDA Grants Orphan Drug Status to PI-88 for Melanoma BRISBANE, Australia, May 3 /PRNewswire-FirstCall/ -- Progen Industries Limited , a progressive Australian anti-cancer drug development...
Half Year Report - Progen on Track to Meet Milestones Further Encouragement for PI-88 from Avastin's Approval BRISBANE, Australia, Feb. 27 /PRNewswire-FirstCall/ -- Progen Industries Limited , a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.